Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Pasmooij, A.M.G.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(6)
+
-
Availability
Open access
(4)
+
-
Metadata Only
(3)
+
-
Creation Date
2022
(2)
+
-
2023
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(5)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(5)
+
-
Scholarly Publications
(2)
+
-
Topic
advanced melanoma
(2)
+
-
Author
Pasmooij, A.M.G.
(7)
+
-
Boer, A. de
(5)
+
-
Dartel, M. van
(5)
+
-
Hilarius, D.L.
(4)
+
-
Ismail, R.K.
(4)
+
-
Wouters, M.W.J.M.
(4)
+
-
Aarts, M.J.B.
(2)
+
-
Aartsma-Rus, A.
(2)
+
-
Berkmortel, F.W.P.J. van den
(2)
+
-
Boers-Sonderen, M.J.
(2)
+
-
Breeschoten, J. van
(2)
+
-
Flier, S. van der
(2)
+
-
Groot, J.W.B. de
(2)
+
-
Haanen, J.B.A.G.
(2)
+
-
Hospers, G.A.P.
(2)
+
-
Kapiteijn, E.
(2)
+
-
Piersma, D.
(2)
+
-
Rijn, R.S. van
(2)
+
-
Suijkerbuijk, K.P.M.
(2)
+
-
Veldt, A.A.M. van der
(2)
+
-
Vreugdenhil, A.
(2)
+
-
Show more
Language
en
(7)
+
-
Search results
(1 - 7 of 7)
show grid
show list
save search
Medication use and clinical outcomes by the Dutch institute for clinical auditing medicines program
Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
Postapproval trials versus patient registries
RNA-based therapies for genodermatoses
Translational and Regulatory Challenges for Exon Skipping Therapies